Corbus Pharmaceuticals to Present Additional Data on the Effects of Resunab(TM) in the Treatment of Pulmonary Infection and Inflammation in Pre-Clinical Models of Cystic Fibrosis

NORWOOD, MA -- (Marketwired) -- 09/22/15 -- (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that it will present additional data on the effects of in ...